Home  |  About SITC  |  Facebook  |  Twitter  |  LinkedIn  |  YouTube  |  Oncology Tube  |  Sitemap

Advances in Cancer Immunotherapy

CME-Certified, Regional Program in collaboration with Moffitt Cancer Center

Saturday, December 7, 2013
8:00 am - 3:00 pm
Tampa Marriott Waterside Hotel and Marina
Tampa, FL

Presentations from this program are available through the program schedule tab.


James J. Mulé, PhD - Moffitt Cancer Center
Vernon K. Sondak, MD - Moffitt Cancer Center

Program Directors

F. Stephen Hodi, Jr., MD - Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS - Rush University Medical Center


Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, this CME-certified program provided an understanding of basic immunology principles underlying the clinical application of immunotherapy, provided insights into the indications and clinical management of patients receiving tumor immunotherapy, and discussed emerging drugs and concepts in the tumor immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, this program summarized central themes in tumor immunotherapy and described the latest research advances and focus on currently approved tumor immunotherapy approaches to facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) management of side effects, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.

Attendees also took advantage of the opportunity for professional networking that promoted collaboration and scientific exchange with experts and clinical oncologists from the surrounding community.


  • The Emerging Role of Combination Tumor Immunotherapy
  • Immunology 101 for the Non-Immunologist
  • Interferon: Indications and Clinical Management in Melanoma
  • Interleukin-2 and Related Cytokines: Indications and Clinical Management
  • Ipilimumab in Melanoma: Indications and Clinical Management
  • New Tumor Immunotherapy Strategies on the Horizon
  • The PD-1/PD-L1 Pathway as a Target in Tumor Immunotherapy
  • Vaccines and Other Forms of Immunotherapy for Breast Cancer
  • Vaccines as Immunotherapy for Other Solid Tumors

Intended Audience

The target audience for this program included practicing clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn increasingly sophisticated principles of tumor immunology and immunotherapy, as well as the role of inflammation in cancer development.

Program Goals

  • Provide a framework of basic immunology for clinical oncologists and facilitate understanding of more sophisticated principles of tumor immunology and immunotherapy
  • Facilitate the translation of cancer immunotherapy research into medical practice by clinical oncologists
  • Provide a common terminology and knowledge base for clinical oncologists from all oncology disciplines and sub-specialties
  • Facilitate an opportunity for dialogue and professional interactions that promote collaboration and scientific exchange

Educational Objectives

Upon completion of this program, the participant should have been able to:

  • Interpret the key principles of tumor immunology and immunotherapy
  • Analyze recent research and clinical applications of tumor immunization, immune coinhibition/costimulation, adoptive immunotherapy, and biomarkers
  • Participate in scientific exchange with colleagues, potential collaborators, and subject matter experts on research and application of cancer immunotherapies
  • Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, their side effects and their efficacy to improve patient outcomes

Jointly-Sponsored by Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer

In collaboration with Moffitt Cancer Center

The Advances in Cancer Immunotherapy series was supported in part by:

  • Amgen
  • Bristol-Myers Squibb
  • Merck
  • Prometheus

Society for Immunotherapy of Cancer
555 East Wells Street, Suite 1100  |  Milwaukee, WI 53202-3823 USA
Tel: +1 414 271 2456  |  Fax: +1 414 276 3349  |  Email: info@sitcancer.org
About SITC  |  Membership  |  Journal  |  Meetings  |  Resources  |  Support SITC
© 2016 Society for Immunotherapy of Cancer. All rights reserved.